Brinzolamide
Primary Therapy Study No. 1.
Methods: A double-masked, randomized,parallel, placebo-controlled multicenter study of brinzolamide 1.0% (b.i.d and t.i.d.) and dorzolamide 2.0% (t.i.d.) in 463 patients for a 3-month treatment period.
Efficacy Results: Mean peak IOP reduction at Month 3: brinzolamide b.i.d.: 16.0 % (4.0 mm Hg). brinzolamide t.i.d.: 18.0% (4.6 mmHg). dorzolamide t.i.d.: 18.7% (4.6 mmHg).
Conclusion: Brinzolamide t.i.d. is equivalent to dorzolamide t.i.d. in peak IOP reduction in a 3-month treatment period.
Brinzolamide Primary Therapy Study No. 2.
Methods: Double-masked, randomized, parallel, active-controlled multicenter study of brinzolamide 1.0% b.i.d., brinzolamide 1.0% t.i.d., dorzolamide 2.0% t.i.d. and timolol 0.5% b.i.d. for a 3 month treatment period with 572 patients.
Efficacy Results: Mean peak IOP reduction at Month 3: brinzolamide b.i.d.: 19.5% (5.1 mmHg); brinzolamide t.i.d.: 20.0% (5.2 mmHg); timolol b.i.d.: 22.5% (5.9 mmHg).
Conclusion: Brinzolamide b.i.d. is equivalent to brinzolamide t.i.d. in peak IOP reduction in a 3 month treatment period.
Brinzolamide Long-Term Therapy Study.
Methods: Double-masked, randomized, parallel, active-controlled multicenter study of brinzolamide 1.0% b.i.d. and t.i.d. and timolol 0.5% b.i.d. for an 18 month treatment period in 379 patients.
Efficacy Results: Mean IOP reductions at trough over 18 months:brinzolamide b.i.d.: 3.3 mmHg; brinzolamide t.i.d.: 3.3 mmHg.
Conclusion: Brinzolamide b.i.d. is equivalent to brinzolamide t.i.d. in IOP reduction at trough over 18 month.
Overall Conclusion: Brinzolamide t.i.d. is equivalent to brinzolamide b.i.d and dorzolamide 2.0% t.i.d. as primary therapy for patients with OAG or OH.